● Recruiting

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Arterial Hypertension · Sponsor: Insmed Incorporated

PhasePhase 3

Planned participants344

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.

This description comes directly from the study's public registry record.

Talk to the study team

Insmed Medical Information · 18444467633 · medicalinformation@insmed.com

Always discuss trial participation with your own doctor first.

Locations (2)

USA008	Santa Barbara, California, United States	Recruiting
USA007	Anderson, South Carolina, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07481981